|
|
|
|
|
|
|
|
| Testimonials From Past PHARLEX® Participants |
| |
| The following comments have been received from recent PHARLEX® participants. They indicate to us that the expectations of
the participants were met.
|
| |
| "This was my first PHARLEX®
conference and the experience was excellent. The format was very productive." Dr. Vidal F. de la Cruz,
Director, Business Development
Cytokine PharmaSciences, Inc., USA |
| "Great, no nonsense
approach." Dr. Bradford W. Baer, VP, Business Development
Angiogenix, Inc., USA |
| "You folks did an excellent
job in organizing the entire event. I am very, very impressed – something that is rare." Prof.
Avi Chaudhuri, President
PAC Med Enterprises, Canada/India |
| "I hope to turn all the
positive leads into deals." Mr. Nicolas Coudurier, General Manager
Laboratories Biocodex, France |
|
“It saves of course a lot of time and money to meet so many different companies in only 2 days. Unexpected collaboration possibilities of great value came up.“
Dr. Marliese Annefeld, Director, International Scientific & Business Development
Rotta Research Laboratorium SpA, Italy |
|
“It was very good chance to find licensees matching our objectives.”
Mr. Hea Jeoung Na, Manager
Hanall Pharmaceutical Co., Ltd., Korea |
|
“Efficient way of making qualified contacts. The atmosphere created at PHARLEX® is conducive to fruitful exchanges.”
Mr. Nigel J. McWilliam, Director, Product Development
CONRAD Program, Eastern Virginia Medical School, USA |
|
“Well organized by Montalier.”
Mr. Wayne Atkinson, General Manager
Hela International Ltd., United Kingdom |
|
 “This
is a wonderful event for making meaningful contacts.”
Dr. Kirby S. Black, Sr. VP R&D, COO
AuraZyme Pharmaceuticals, Inc. USA |
|
“This is truly
a great idea. I will certainly attend again and recommend it to others.”
Ms. Justyna Lipinska, Technology Transfer Associate
The CBR Institute for Biomedical Research, Inc., USA |
|
“For a start-up
company with limited resources, this is an ideal event to meet in a short time with several potential strategic partners.”
Mr. Thomas J. Svoboda, CEO
Pro-Med AG, Switzerland |
|
“It was a very good
format. The meeting helped to compress my time where it would have taken several weeks/month to meet with these companies.”
Mr. Michael T. Mallon, VP, Business Development for North America
Phoqus Pharmaceuticals Limited, United Kingdom |
|
“Preview of profiles
and objectives as well as half-hour table top appointments are excellent."
Mr. Alex M. Blaine, CEO
Blaine Pharmaceuticals, Inc., USA |
|
“The whole process is very efficient. There isn't excess fluff or other activities that get in the
way of getting business done. All attendees want and have the authority to make deals.”
Mr. Timothy O'Halla, Director, New Products Marketing
Ferndale Laboratories, Inc., USA |
|
"I found the meeting to be highly efficient, targeted and productive from both
the in-licensing and out-licensing perspectives."
Mr. Bo Allen, VP, Market
and Business Development
Rare Disease
Therapeutics, Inc., USA |
|
“30 minutes meetings were ideal length. Ability to schedule
meetings in advance provided superior efficiency.”
Mr. David
Engelberg, Director, Business Development
Celltech
Pharmaceuticals, Inc., USA |
|
"It was a very good experience... I will recommend that meeting to my
partners' companies."
Dr. Mostafa M. Omar, President & CEO
Phytoceuticals,
Inc., USA |
|
“I was quite impressed and saw a definite value in
attending…”
Dr. Daniel C. Böck, VP, Business Development and
Licensing
Procyon Biopharma Inc., Canada |
|
“You organized a terrific conference.”
Mr. Barry M. Deutsch, CFO
& VP, Business Development
Ovation Pharmaceuticals,
Inc., USA |
|
“I liked the
efficiency and “simplicity” of the pre-meeting information exchange as well as the meeting itself.”
Dr.
Bengt Westrin, Director, Business Development
Camurus AB, Sweden |
|
| Many more comments could have been listed.
However, the above testimonials have been selected in an attempt to provide unique perspectives without being repetitive. |
|
|
| |
|
 |
| |
 |
|
|
